Indoco Remedies gains as its AnaCipher CRO clears USFDA inspection with Zero 483s
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Indoco Remedies is currently trading at Rs. 355.15, up by 0.65 points or 0.18% from its previous closing of Rs. 354.50 on the BSE.
The scrip opened at Rs. 357.00 and has touched a high and low of Rs. 371.65 and Rs. 350.50 respectively. So far 4832 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 513.00 on 20-Oct-2021 and a 52 week low of Rs. 321.05 on 12-May-2022.
Last one week high and low of the scrip stood at Rs. 373.85 and Rs. 350.50 respectively. The current market cap of the company is Rs. 3269.96 crore.
The promoters holding in the company stood at 58.69%, while Institutions and Non-Institutions held 19.24% and 22.07% respectively.
Indoco Remedies’ Clinical Research Organisation, AnaCipher, located in Hyderabad, was inspected by the United States Food and Drug Administration (USFDA) from September 12 to September 16, 2022. The clinical phase of inspection covered three BA/BE studies submitted by clients to the USFDA and was successfully concluded with zero 483s. This is the seventh successive USFDA inspection with ZERO 483s for AnaCipher CRO.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
